These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26818417)

  • 21. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM; Li W; Jiang XL
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
    Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.
    Macaluso FS; Maida M; Ventimiglia M; Renna S; Cottone M; Orlando A
    Inflamm Bowel Dis; 2019 May; 25(6):987-997. PubMed ID: 30590590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Dohos D; Hanák L; Szakács Z; Kiss S; Párniczky A; Erőss B; Pázmány P; Hegyi P; Sarlós P
    Aliment Pharmacol Ther; 2021 Jan; 53(2):220-233. PubMed ID: 33249621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis.
    Chen L; Xu CJ; Wu W; Ding BJ; Liu ZJ
    J Dig Dis; 2021 Jul; 22(7):408-418. PubMed ID: 34048629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
    Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
    World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
    Ford AC; Achkar JP; Khan KJ; Kane SV; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):601-16. PubMed ID: 21407188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis.
    Gisbert JP; Linares PM; McNicholl AG; Maté J; Gomollón F
    Aliment Pharmacol Ther; 2009 Jul; 30(2):126-37. PubMed ID: 19392869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Danese S; Fiorino G; Peyrin-Biroulet L; Lucenteforte E; Virgili G; Moja L; Bonovas S
    Ann Intern Med; 2014 May; 160(10):704-11. PubMed ID: 24842416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the management of ulcerative colitis.
    Taba Taba Vakili S; Taher M; Ebrahimi Daryani N
    Acta Med Iran; 2012; 50(6):363-72. PubMed ID: 22837114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.